Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142388 | 0.81 | LMNA (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL580188 | 0.72 | MMP2 (0.59) | ADRA1ALMNAMMP2TSHRCYP3A4 | |
| SCHEMBL6142549 | 0.72 | LMNA (0.58) | ADRA1ALMNAMMP2TSHRCYP3A4 | |
| SCHEMBL6142363 | 0.71 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| Bromide SCHEMBL27032828 | 0.70 | MMP2 (0.57) | ADRA1ALMNAMMP2TSHRCYP3A4 | |
| Phenanthroline SCHEMBL9806287 | 0.70 | CCR1 (0.84) | ADRA1ALMNAMMP2TSHRCYP3A4 | |
| SCHEMBL6142571 | 0.70 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL6142535 | 0.70 | CYP3A4 (0.49) | ADRA1ALMNAMMP2TSHRCYP3A4 | |
| Phenanthroline SCHEMBL8150927 | 0.70 | CCR1 (0.94) | ADRA1ALMNAMMP2TSHRCYP3A4 | |
| Phenanthroline SCHEMBL28895954 | 0.68 | CCR1 (0.80) | ADRA1ALMNAMMP2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944604-B1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2005-01-12 | — | — | EP | claimed |
| CN-1104422-C | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 2003-04-02 | — | — | CN | claimed |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-09-12 | — | — | US | claimed |
| US-6391878-B2 | COMPOUNDS SUCH AS (4,7-DIMETHYLBENZIMIDAZOL-5-YL)GUANIDINE; TREATING NASAL CONGESTION, OTITIS MEDIA, ASTHMA, PAIN, MIGRAINE, GASTROINTESTINAL DISORDER, ULCER | THE PROCTER & GAMBLE COMPANY | 2002-05-21 | — | — | US | claimed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | claimed |
| CN-1242006-A | Guanidinyl heterocyclic compounds as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 2000-01-19 | — | — | CN | claimed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0944604-B1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| CN-1104422-C | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 2003-04-02 | — | — | CN | disclosed |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-09-12 | — | — | US | disclosed |
| US-6391878-B2 | COMPOUNDS SUCH AS (4,7-DIMETHYLBENZIMIDAZOL-5-YL)GUANIDINE; TREATING NASAL CONGESTION, OTITIS MEDIA, ASTHMA, PAIN, MIGRAINE, GASTROINTESTINAL DISORDER, ULCER | THE PROCTER & GAMBLE COMPANY | 2002-05-21 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| US-6225331-B1 | FOR THERAPY AND PROPHYLAXIS NASAL CONGESTION, OTITIS MEDIA, AND SINUSITIS, TREATING COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA, BENIGN PROSTATIC HYPERTROPHY, CARDIOVASCULAR DISORDERS, GLAUCOMA, HYPEREMIA, CONJUNCTIVITIS | THE PROCTER & GAMBLE COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | disclosed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 4/4885ADRA2C 3/4885 |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | ADRB2, ADRA2C, ADRA2B | ADRA2A 5/4885ADRA2B 3/4885ADRA2C 2/4885 |
| US-20020128481-A1 | Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885ADRA2B 6/4885ADRA2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.